Iowa House Bill HSB186

Iowa 2025-2026 Regular Session

• Introduced: 2/17/25
• Refer: 2/17/25

Caption

A bill for an act relating to medication abortions including required informed consent and the dispensing of abortion-inducing drugs to patients within the state.(See HF 775.)

Impact

If enacted, HSB186 would significantly modify existing laws related to medication abortions by introducing a requirement for physicians to obtain written certification from patients, indicating that they have been informed about the risks and potential options available should they wish to reverse the abortion. This shift aims to centralize the understanding of medication abortion procedures and the alternative possibilities, which may influence women's choices and access to care in the state of Iowa. Additionally, the bill requires the Department of Health and Human Services to create and disseminate informational materials on the reversal of medication abortion effects.

Summary

House Study Bill 186 aims to amend the provisions surrounding medication abortions in Iowa. This legislation focuses on ensuring that women have comprehensive informed consent before undergoing a medication abortion and mandates specific disclosures about the risks and alternatives associated with abortion-inducing drugs such as mifepristone. The bill establishes requirements for healthcare facilities, such as conspicuously posting information about the potential for reversal of medication abortions, which advocates for this bill argue is crucial for patient autonomy and informed decision-making.

Contention

The bill has sparked notable debate among legislators and advocates. Supporters argue that it empowers women by ensuring they have all necessary information about medication abortions, including information about potential reversal procedures. Critics, however, contend that the requirement to inform women of the possibility of reversing a medication abortion may mislead patients about the nature of these procedures and the reality of medication abortion effectiveness. They argue that the additional steps required by HSB186 may create unnecessary barriers to accessing timely healthcare, especially in sensitive situations like unintended pregnancies.